Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FK717
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,454
Award facts
- Contract value 100% obligated
- $20,454.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,454.05 delivery order to AmerisourceBergen Drug Corp on December 18, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and is scheduled for completion by December 19, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location. The delivery order is issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion prime vehicle (SPE2DX) that extends through December 2026 and serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs.
Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions. This delivery order represents a routine pharmaceutical replenishment supporting military and defense medical supply requirements. AmerisourceBergen Drug Corp's federal procurement portfolio demonstrates extensive experience fulfilling Defense Logistics Agency pharmaceutical needs across multiple therapeutic domains, with contract awards ranging from small-value transactions to substantial orders. The company's qualification as a prime vendor under the DLA's pharmaceutical supply chain reflects its capability to meet federal medical procurement standards through open competition and its established role as a critical supplier to military healthcare systems and the Defense Health Agency.
Quick answers
Who was awarded contract SPE2DR26FK717?
SPE2DR26FK717 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FK717 worth?
The government has obligated $20,454 on SPE2DR26FK717.
Is contract SPE2DR26FK717 an order under another contract?
Yes. SPE2DR26FK717 is a delivery order under SPE2DR25D1104, an indefinite delivery contract.
Was contract SPE2DR26FK717 competed?
The extent of competition for SPE2DR26FK717 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award